GDR genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. genedrive plc has a collaboration agreement with Thermo Fisher Scientific Inc. to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.…
Industry Peers
Diagnostics & ResearchKey Statistics
About genedrive (LON: GDR)
›
genedrive (LON: GDR) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 43 employees.
The shares were at 0.9000 GBp on 19 November 2026, up 19.2% over 52 weeks. Its 52-week range is 0.7150 GBp to 1.550 GBp: the price is 41.9% below the high and 25.9% above the low.
Its market capitalisation is 14.45M GBP.
genedrive reports return on equity of -363.8%, an operating margin of -462.4% and revenue up 62.9% year over year.
Its debt exceeds its cash by 113.00K GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.